Adaptive Oncology IP Licensing Office

[About]

This portal serves as the official licensing and intellectual property management channel for a proprietary adaptive low-dose multi-drug cancer control methodology.

[Clinical Validation & Proof of Concept (PoC)]

Our predictive model and clinical algorithm have achieved complete Proof of Concept (PoC) through a rigorous clinical evaluation of 308 patient cases.

As detailed in our official white paper, "Beyond Precision Medicine: The Microcirculatory Compartment Theory and Systemic Host Defense Profiling for Adaptive Low-Dose Multi-Drug Cancer Control" (published on SSRN (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=7428729)), this methodology systematically profiles host defense mechanisms to dynamically optimize multi-drug regimens, establishing a highly validated, data-driven approach to adaptive oncology.

[Intellectual Property & Next-Gen Implementation]

The core mechanism, algorithmic selection logic, and training frameworks are fully protected and exclusively managed under:

Japanese Patent No. 7370046: Method for Selecting Anticancer Agents

To facilitate clinical adoption, the core methodology is also being integrated into an advanced AI-driven framework to encode and scale the treatment algorithm for automated clinical support.

[Licensing & Contact]

Access to extended clinical datasets, validation metrics, AI platform previews, and commercial licensing terms is strictly gated to protect our intellectual property.

Authorized corporate development teams, AI healthcare researchers, and strategic partners may request a Mutual Non-Disclosure Agreement (mNDA) to initiate preliminary discussions and technical previews.

Direct Inquiries: licensing@ginza-adaptive-oncology-licensing.com